APA (7th ed.) Citation

McIlroy, G., Gaskell, C., Jackson, A., Yafai, E., Tasker, R., Thomas, C., . . . McMullin, M. F. (2025). Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): Study protocol for a multicentre, open-label, Bayesian phase II trial. BMC Cancer, 25(1), 1. https://doi.org/10.1186/s12885-024-13383-3

Chicago Style (17th ed.) Citation

McIlroy, Graham, et al. "Fedratinib Combined with Ropeginterferon Alfa-2b in Patients with Myelofibrosis (FEDORA): Study Protocol for a Multicentre, Open-label, Bayesian Phase II Trial." BMC Cancer 25, no. 1 (2025): 1. https://doi.org/10.1186/s12885-024-13383-3.

MLA (9th ed.) Citation

McIlroy, Graham, et al. "Fedratinib Combined with Ropeginterferon Alfa-2b in Patients with Myelofibrosis (FEDORA): Study Protocol for a Multicentre, Open-label, Bayesian Phase II Trial." BMC Cancer, vol. 25, no. 1, 2025, p. 1, https://doi.org/10.1186/s12885-024-13383-3.